Results 161 to 170 of about 4,977 (213)

Tiotropium Bromide

Drugs, 2002
Tiotropium bromide is an anticholinergic bronchodilator that antagonises muscarinic M(1), M(2) and M(3) receptors. It dissociates more slowly from M(1) receptors and, importantly, from M(3) receptors (which are located in bronchial smooth muscle) than from M(2) receptors and subsequently has a long duration of action permitting once-daily ...
Karen M, Hvizdos, Karen L, Goa
  +6 more sources

Tiotropium Bromide

Chest, 2004
Tiotropium bromide is a novel, inhaled, once-daily anticholinergic bronchodilator that has recently been approved in the United States for use in patients with COPD. Its unique feature is the persistence of bronchodilation for > 24 h due to prolonged M(3) muscarinic receptor blockade.
Cynthia Mundy, Peter Kirkpatrick
  +6 more sources

Tiotropium bromide

Expert Opinion on Investigational Drugs, 2001
Tiotropium bromide is a new long-lasting anticholinergic drug which, like ipratropium bromide, is a quaternary ammonium derivative. It binds with high affinity to muscarinic receptors but dissociates very slowly from M(1)- and M(3)-muscarinic receptors.
openaire   +2 more sources

Intermittent Tiotropium Bromide for Episodic Wheezing: A Randomized Trial

Pediatrics, 2022
BACKGROUND AND OBJECTIVES Options to treat and prevent episodic wheezing in children are scarce. Our objective was to assess the efficacy of intermittent tiotropium bromide treatment in early childhood episodic wheezing.
Pelkonen Anna S., Kotaniemi-Syrjänen Anne, Rahiala Eero, Aito Henrikka, Malmström Kristiina, Malmberg L. Pekka, Mäkelä Mika J., Jauhola Outi, Koponen Petri, Sarna Seppo, Klemola Timo, Pelkonen Anna S., Kotaniemi-Syrjänen Anne, Rahiala Eero, Aito Henrikka, Malmström Kristiina, Malmberg L. Pekka, Mäkelä Mika J., Jauhola Outi, Koponen Petri, Sarna Seppo, Klemola Timo   +21 more
openaire   +2 more sources

Tiotropium bromide for cystic fibrosis

Expert Opinion on Orphan Drugs, 2015
Introduction: Airway obstruction is a common feature in cystic fibrosis (CF) patients and bronchodilators, either short or long acting, are widely used in CF care.Areas covered: Tiotropium bromide is a long-acting anticholinergic muscarinic receptor antagonist, leading to bronchodilation and to a lesser extent reduction of airway secretions.
Saadoun Bin-Hasan, Felix Ratjen
openaire   +1 more source

Tiotropium bromide for chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine, 2009
Tiotropium bromide is a long-acting, once-daily inhaled anticholinergic approved for the treatment of chronic obstructive pulmonary disease (COPD). Functional and kinetic selectivity for muscarinic (M) receptors, M(1) and M(3), in the lung permit sustained bronchodilation in moderate and severe COPD.
A James, Mamary, Gerard J, Criner
openaire   +2 more sources

Safety and pharmacological profile of tiotropium bromide

Expert Opinion on Drug Safety, 2009
Chronic obstructive pulmonary disease (COPD) is associated with progressive airflow obstruction and is characterized by a high risk of morbidity and mortality. With early detection and treatment, the natural history of this disease may be improved. So far, bronchodilator therapy is the most important treatment for COPD.
P. Santus, F. Di Marco
openaire   +2 more sources

Olodaterol + tiotropium bromide for the treatment of COPD

Expert Review of Respiratory Medicine, 2016
Patients suffering from COPD not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Addition of a LABA to a LAMA induces a larger bronchodilation than that obtained with the LAMA as monotherapy and also improves many patient-reported outcomes.
Calzetta L., Ciaprini C., Puxeddu E., Cazzola M.   +3 more
openaire   +4 more sources